HERCRNA Trademark

Trademark Overview


On Thursday, June 9, 2022, a trademark application was filed for HERCRNA with the United States Patent and Trademark Office. The USPTO has given the HERCRNA trademark a serial number of 97450050. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, July 30, 2024. This trademark is owned by Esperovax, Inc.. The HERCRNA trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Modified cells for medical or clinical use; Pharmaceuticals for the prevention or treatment of COVID19; Pharmaceuticals for the prevention or treatment of infection with respiratory syncytial virus (RSV); Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic age...
hercrna

General Information


Serial Number97450050
Word MarkHERCRNA
Filing DateThursday, June 9, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, July 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements


Goods and ServicesVaccines; Modified cells for medical or clinical use; Pharmaceuticals for the prevention or treatment of COVID19; Pharmaceuticals for the prevention or treatment of infection with respiratory syncytial virus (RSV); Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention of infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of infection, disease, or disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 21, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEsperovax, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPlymouth, MI 48170

Party NameEsperovax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPlymouth, MI 48170

Trademark Events


Event DateEvent Description
Monday, June 13, 2022NEW APPLICATION ENTERED
Tuesday, June 21, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 23, 2023ASSIGNED TO EXAMINER
Sunday, April 2, 2023NON-FINAL ACTION WRITTEN
Sunday, April 2, 2023NON-FINAL ACTION E-MAILED
Sunday, April 2, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, July 1, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Saturday, July 1, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, October 2, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 2, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 25, 2023ASSIGNED TO EXAMINER
Wednesday, October 25, 2023ASSIGNED TO EXAMINER
Thursday, November 2, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 30, 2024SOU EXTENSION 1 GRANTED
Tuesday, July 30, 2024SOU EXTENSION 1 FILED